Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis
SAN DIEGO – March 11, 2014 – Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing.
St. Louis Business Journal
March 7, 2014
Brian Feldt, Reporter
Two venture firms with St. Louis ties have invested in a Fort Worth-Texas-based pharmaceutical company’s $55 million financing round.
ZS Pharma, which is developing treatments for kidney, cardiovascular, and liver disorders, closed on a $55 million Series D financing round on Wednesday.Read More
March 3, 2014
By Wayne Koberstein, executive editor
Not to build a platform, but to create new, FDA -approved therapeutics for unserved indications in the ear, this developer focuses on novel delivery.Read More
ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for Hyperkalemia
Coppell, Texas – March 5, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing.Read More